

---

# CAR-T Therapy Discharge and Follow Up. CAR-T Service Pathway – Post Infusion

---

Lead Organisation: iMATCH

Author: The Christie NHS Foundation Trust

Version Number: 4.0

Finalisation Date: 04/25

## End user rights:

This document is shared with permission for re-use to distribute, remix, adapt, and build upon the material in any medium or format for non-commercial purposes only, so long as the attributions listed below are given.

**Attributions:** The Christie NHS Foundation Trust

This document is made available under a Creative Commons Attribution-NonCommercial 4.0 International License as described here: <https://creativecommons.org/licenses/by-nc/4.0/>

The information, materials and any opinions contained in this document are provided for general information and educational purposes only, are not intended to constitute legal, medical or other professional advice and should not be relied on or treated as a substitute for specific advice relevant to particular circumstances. Although we make all reasonable efforts to ensure the information is up to date, we make no representations, warranties or guarantees in that regard. In no event shall the creator(s) be liable for any direct, indirect, special, consequential or other claims, losses or damages that are related to the use or reliance whatsoever in the content of the document or any part thereof, except to the extent that such liability cannot be excluded by law. We do not seek to exclude or limit in any way our liability to the user for personal injury or death caused as a result of our negligence or seek to exclude or limit our liability for fraud or fraudulent misrepresentation by us.


We reserve the right to make changes and improvements to any information contained within this document, at any time and without notice. Where this document contains hyperlinks to other websites operated by parties not connected to us, such hyperlinks are provided for your reference only. We do not control such websites and are not responsible for their contents.

The inclusion of hyperlinks from this document or the website to such websites does not imply any endorsement of the material on such websites or any association with their operators. We accept no responsibility of any nature whatsoever for linked web sites or any information contained in them.

Funded by



Coordinated by





## Chimeric Antigen Receptor T-Cell Therapy Discharge and Follow Up. CAR-T Service Pathway – Post Infusion

Author	
Revision	4.0
Changes from previous Version	Format change + update to reflect JACIE V8 B5.1.13 in the introduction, also monitoring of patients to meet the provision of long term on going care B5.1.14 (p4/10)

### Table of Contents

<b>1.0 Introduction &amp; Scope.....</b>	<b>3</b>
<b>2.0 Responsibilities .....</b>	<b>3</b>
<b>3.0 Objectives.....</b>	<b>4</b>
<b>4.0 Training and Competence .....</b>	<b>4</b>
<b>5.0 Procedural Statements .....</b>	<b>4</b>
5.1 Hospital Discharge.....	4
5.2 Patient Monitoring.....	6
5.3 Patient Monitoring Beyond Day+28.....	6
5.4 Day+28 to Day+100.....	6
5.5 Beyond Day+100.....	7
5.6 Schedule of Assessments.....	7
5.7 Quality of Life Assessments.....	8
5.8 Prophylaxis and Supportive Medications .....	8
5.9 Immunisations .....	9
<b>6.0 Monitoring Compliance .....</b>	<b>9</b>
<b>7.0 Dissemination/Distribution .....</b>	<b>9</b>
<b>9.0 References and Related Forms, Labels, Policies and Procedures</b>	<b>9</b>
<b>10.0 Approval Process &amp; Review Process .....</b>	<b>11</b>

**PRINTED COPIES MAY NOT BE THE MOST CURRENT VERSION OF THIS DOCUMENT. ALWAYS REFER TO Q PULSE FOR THE MOST UP TO DATE VERSION**

Chimeric Antigen Receptor T-Cell Therapy Discharge and Follow-Up. CAR-T Service Pathway – Post Infusion		Version 4.0
Index Number: CLN-99		Author:
Effective Date: April 2025	Review Date: See Q Pulse	Page 2 of 11



## 1.0 Introduction & Scope

This document reflects the international consensus recommendations from EBMT, JACIE and ASTCT, and complies with the NHS England CAR-T service specification for allogeneic transplant centres commissioned as CAR-T therapy centres with attending transplant physicians.

This procedure ensures safe discharge and follow-up for patients following Chimeric Antigen Receptor (CAR) T-cell therapy. It defines the expected treatments, tests, medical and nursing care at the required timescale according to the individual patient's condition and protocol with the explicit recognition of the potential complications of IEC therapies and the need for monitoring of the patients to ensure any adverse complications are quickly spotted and management strategies effected in a timely manner. Patients treated within a clinical trial will also follow the relevant trial protocol.

In contrast to post autologous and allogeneic transplant patients, little is known about the long-term effects of CAR T cell therapy beyond 1-2 years. Only a small cohort of patients has been followed for more than 2 years. The identified complications include prolonged cytopenias, hypogammaglobulinemia, delayed B and T cell immune reconstitution with consequent atypical infection.

Other longer-term toxicities may emerge with longer term follow up of larger cohorts of patients.

## 2.0 Responsibilities

The Programme Director, Quality Manager, Stem Cell Laboratory Manager and Ward Nursing Leads are responsible for ensuring staff who are required to carry out activities described in this document receive a copy via the Q Pulse document distribution system.

All staff who are required to undertake activities described in this document must read and acknowledge receipt of this document, and where training is required shall not undertake described activities unsupervised until relevant training has been delivered.

**Ambulatory Care Nursing and Clerical Teams** are responsible for the organisation of visits and nursing care for the first 28 days post CAR-T infusion.

**PRINTED COPIES MAY NOT BE THE MOST CURRENT VERSION OF THIS DOCUMENT. ALWAYS REFER TO Q PULSE FOR THE MOST UP TO DATE VERSION**

Chimeric Antigen Receptor T-Cell Therapy Discharge and Follow-Up.  
CAR-T Service Pathway – Post Infusion

Version 4.0

Index Number: CLN-99

Author:

Effective Date: April 2025

Review Date: See Q Pulse

Page 3 of 11



**Research Nursing Teams** are responsible for coordinating all trial specific requirements for patients in clinical trials

**Auto/CAR-T Therapy Coordinator/Haematology CNS/Lymphoma CNS** are responsible for ensuring the patient has been appropriately informed of all relevant information prior to commencing shared care arrangements. To liaise with referring teams with regarding patient needs and to act as a point of support and reference for patients. Undertake annual reviews to meet JACIE, EBMT, NCCP and NHS England service specifications.

**Cellular/CAR-T Therapies Clinical Lead** will provide oversight of the overall clinical care and data returns of patients and once clinically appropriate, authorise shared care arrangements of the patient with the referring Consultant, supporting long-term follow-up by The Christie nursing and referring consultant teams.

**Transplant Program Lead** takes overall responsibility for cellular therapies including CART treatment

**Trial Principal Investigator** is responsible for patients enrolled in clinical trials

### 3.0 Objectives

The objective of this SOP is to give detail of the discharge and follow up of CAR-T patients in the Haematology Programme at The Christie Hospital

### 4.0 Training and Competence

Prior to implementation of any new or revised procedure there shall be a review and if considered appropriate training and competency shall be delivered prior to implementation of the procedure.

### 5.0 Procedural Statements

#### 5.1 Hospital Discharge

Exact timing of discharge will be based on the clinical condition of the patient, availability of carers, pre-existing co-morbidities, distance from home to hospital and suitability for ambulatory discharge care. The Palatine attending haematology consultant will be responsible for assessing the suitability of the patient discharge supported by the CAR-T Lead.

**PRINTED COPIES MAY NOT BE THE MOST CURRENT VERSION OF THIS DOCUMENT. ALWAYS REFER TO Q PULSE FOR THE MOST UP TO DATE VERSION**

Chimeric Antigen Receptor T-Cell Therapy Discharge and Follow-Up.  
CAR-T Service Pathway – Post Infusion

Version 4.0

Index Number: CLN-99

Author:

Effective Date: April 2025

Review Date: See Q Pulse

Page 4 of 11



**Duration of Admission and Timing of Discharge**

Patients undergoing CAR-T therapy will be closely followed up as inpatients or in ambulatory care until day+28 or longer if required for clinical trials protocols

- All patients will remain inpatients until at least day+14 or as directed by a relevant trial protocol
- Selected patients who are clinically stable with no evidence of significant treatment related complications beyond asymptomatic bone marrow suppression may be considered for discharge to home or ambulatory care at day+14
- Patients who are unstable, or who develop significant complications (eg treatment related or disease progression) may require longer time in hospital or ambulatory care as directed by the Attending Consultant or CAR-T lead.

**Discharge Planning**

All patients must remain within a 1-hour drive of The Christie Hospital until at least day+28 (or longer as above). This can be either from home, remaining as an inpatient, or suitable close to site accommodation (eg ambulatory care). Where patients are discharged before day+28, the following will apply:

- Patients who are stable should only be discharged Mon-Thurs and not on public holidays.
- All patients should have a carer available to stay with them until day+28 or resolution of neurotoxicity/ICANS whichever is longer.
- Patients must be aware of the requirements for life long irradiated blood products
- Patients must monitor their temperature regularly and to report fever or any symptoms of being unwell to the Hotline.
- Patients must have contact details for the Hotline, Cellular Therapy Team, Ambulatory care unit
- Patient will receive CAR-T Product patient card
- Patients must be made aware of the potential symptoms of delayed neurological toxicity and advised that they should refrain from driving or operating heavy or potentially dangerous machines until at least 8 weeks post infusion or until resolution of neurologic adverse reactions if longer. Patients experiencing a seizure should inform the DVLA and refrain from driving until authorised.

**PRINTED COPIES MAY NOT BE THE MOST CURRENT VERSION OF THIS DOCUMENT. ALWAYS REFER TO Q PULSE FOR THE MOST UP TO DATE VERSION**

Chimeric Antigen Receptor T-Cell Therapy Discharge and Follow-Up.  
CAR-T Service Pathway – Post Infusion

Version 4.0

Index Number: CLN-99

Author:

Effective Date: April 2025

Review Date: See Q Pulse

Page 5 of 11



Discharge will be facilitated by the ward nurses, CNS team and CAR-T/transplant coordinators

## 5.2 Patient Monitoring

Monitoring patients post IEC administration, including recognition of cellular therapy complications and emergencies requires rapid notification of the responsible clinical team. In addition to the described monitoring there is a requirement for the provision of long term follow up care post infusion, this will be detailed to the patient as part of the ongoing care plan.

Patients discharged before day+28 will be monitored in ambulatory care on Mon/Wed/Fri and will require the following assessments:

- ICANS and CRS assessment
- Weight and observations
- Blood tests - FBC and Christie profile, CRP, Ferritin, coagulation monitoring

All patients will be reviewed by nursing staff. A medical review is indicated in the vent that patients are unwell, deteriorating, exhibiting new symptoms, have observations or blood tests out of normal range or where nursing team or patients have any concerns.

Patients will also be reviewed on a weekly basis in the Tuesday pm cellular therapies clinic.

## 5.3 Patient Monitoring Beyond Day+28

Patients can be discharged home and out of ambulatory care without restrictions on distance from The Christie if they are stable with no evidence of any significant treatment related toxicity.

## 5.4 Day+28 to Day+100

Patients will be followed up in the Tuesday pm Cellular Therapies Clinic to day+100; the frequency of appointments (normally weekly initially and then extended to 2-4 weekly) will be determine on an individual patient basis. Shared care arrangements with local referring centres should be considered for patients travelling significant distances to the Christie; a documented plan of care must be in place with the referring team. Extended intensive follow up may be needed per section 3.3 for

**PRINTED COPIES MAY NOT BE THE MOST CURRENT VERSION OF THIS DOCUMENT. ALWAYS REFER TO Q PULSE FOR THE MOST UP TO DATE VERSION**

Chimeric Antigen Receptor T-Cell Therapy Discharge and Follow-Up.  
CAR-T Service Pathway – Post Infusion

Version 4.0

Index Number: CLN-99

Author:

Effective Date: April 2025

Review Date: See Q Pulse

Page 6 of 11



patients with significant treatment related complications or those discharged from the ward after day+28.

### 5.5 Beyond Day+100

Patients (lymphoma) who are clinically stable and responding to treatment should be referred back to local teams for follow up. Requirements for monitoring (see section 3.5) and follow up must be shared with the referring team. Patients will also be followed up at the Christie (in person or remote consultation) every 6 months (year 1) and then annually in order to monitor progress and to collect data required for EBMT/BSBMT. Additional follow up appointments at the Christie may be required in the event of complications arising from treatment, suspected relapse or as requested by the referring team

Additional follow up visits may be required for patients in clinical trials per protocol,

### 5.6 Schedule of Assessments

Schedule for disease and CAR-T monitoring is as per the table below

Day	Disease/complication monitoring	CAR-T monitoring
+30	<b>NHL</b> – PET scan (and marrow or MRD if indicated)  <b>ALL</b> - marrow, MRD, imaging as indicated  Ferritin/CRP/LDH Virology (parvovirus, JC/BK, HHV 6/7/8) if positive at consent visit	Immune monitoring  Immunoglobulins
+60	<b>ALL</b> - marrow, MRD, imaging as indicated	Immune monitoring  Immunoglobulins
+100	<b>NHL</b> – PET scan (and marrow or MRD if indicated)	Immune monitoring  Immunoglobulins

**PRINTED COPIES MAY NOT BE THE MOST CURRENT VERSION OF THIS DOCUMENT. ALWAYS REFER TO Q PULSE FOR THE MOST UP TO DATE VERSION**

Chimeric Antigen Receptor T-Cell Therapy Discharge and Follow-Up.  
CAR-T Service Pathway – Post Infusion

Version 4.0

Index Number: CLN-99

Author:

Effective Date: April 2025

Review Date: See Q Pulse

Page 7 of 11



	<b>ALL</b> - marrow, MRD, imaging as indicated  Vitamin B12, vitamin D, folate	
Later follow up	<b>ALL</b> - marrow, MRD, imaging as indicated every 3 months until 24 months post treatment  <b>NHL</b> - PET scan at 12 months and thereafter only if concerns about disease progression	Immune monitoring  Immunoglobulins  <b>All performed 3 monthly to 24 months post treatment or normalisation</b>
Further specific investigations may be undertaken as clinically indicated		

### 5.7 Quality of Life Assessments

Cellular Therapy Coordinator/Haematology CNS will provide quality of life assessments (FACT-BMT) to all CAR-T patients' pre-admission (during consent visit), day +28 and day +100, the results will be reviewed and audited annually by the Haematology CNS team.

### 5.8 Prophylaxis and Supportive Medications

PCP prophylaxis - All patients will receive a dose of Pentamidine nebuliser pre-hospital discharge with continuation of this method of PCP prophylaxis or switch to alternative medication such as Septrin or Atovaquone will be guided by the CAR-T Clinic and based on the patient's blood counts. PCP prophylaxis should ideally continue for at least 12 months or until lymphocyte count is consistently about 1 and CD4 count greater than 200, whichever is longer. Patients with Toxoplasma IgG exposure or patients with previously PCP infection should receive Atovaquone 750mg twice a day or septrin 960mg once a day on Mon/Wed/Fri.

Antiviral prophylaxis – aciclovir 400mg BD to be continued for a minimum of 12 months post CART therapy or until Lymphocyte count is consistently about 1 and CD4 count greater than 200, whichever is longer.

**PRINTED COPIES MAY NOT BE THE MOST CURRENT VERSION OF THIS DOCUMENT. ALWAYS REFER TO Q PULSE FOR THE MOST UP TO DATE VERSION**

Chimeric Antigen Receptor T-Cell Therapy Discharge and Follow-Up.  
CAR-T Service Pathway – Post Infusion

Version 4.0

Index Number: CLN-99

Author:

Effective Date: April 2025

Review Date: See Q Pulse

Page 8 of 11



Levofloxacin is only required in patients where the neutrophil count is below 1.0, including those who require GCSF support.

Primary antifungal prophylaxis with fluconazole to continue until neutrophils are greater than 1.0, including those who require GCSF support.

Secondary antifungal prophylaxis or treatment with posaconazole to continue until neutrophils are greater than 1.0

GCSF support – Long term cytopenias are expected in this patient group and should be managed with GCSF support with aim of maintaining neutrophils  $>1 \times 10^9/l$

IVIg replacement is with 0.4-0.6 g/kg every 4-6 weeks will be considered from day+28 for deficiency secondary to CAR-T cell therapy, when IgG level is  $<4g/l$  and recurrent infections per NHSE guidance. Treatment will be discontinued after recovery of CD19 cells in the peripheral blood and nadir IgG greater than 4 g/l.

### 5.9 Immunisations

CAR-T patients will be immunised one year post infusion at the clinician’s discretion, full details are available in the CLN-101 “Recommendations for Immunisation” and “WRD-88 Travel and immunisation in stem cell transplant patients”.

### 6.0 Monitoring Compliance

Compliance to this document will be monitored by a combination of audit where applicable, non-conformance monitoring and Datix incident reporting.

### 7.0 Dissemination/Distribution

This document will be distributed to staff members who need visibility of the document via Q Pulse.

### 9.0 References and Related Forms, Labels, Policies and Procedures

CLN-14 Coordinating a CAR-T therapy (including TCR)

**PRINTED COPIES MAY NOT BE THE MOST CURRENT VERSION OF THIS DOCUMENT. ALWAYS REFER TO Q PULSE FOR THE MOST UP TO DATE VERSION**

Chimeric Antigen Receptor T-Cell Therapy Discharge and Follow-Up.  
CAR-T Service Pathway – Post Infusion

Version 4.0

Index Number: CLN-99

Author:

Effective Date: April 2025

Review Date: See Q Pulse

Page 9 of 11



CLN-118 Inpatient management of patients receiving immune effector cells (including CAR-T cells)

CLN-115 Neurological disease in stem cell transplantation and cellular therapy

AMB-23 Kymriah CAR-T - ALL Nursing Protocol for Haematology & TYA Ambulatory Care Unit

AMB-21 Kymriah CAR-T - DLBCL Nursing Protocol for Haematology & TYA Ambulatory Care Unit

AMB-22 Yescarta CAR-T - DLBCL Nursing Protocol for Haematology & TYA Ambulatory Care Unit

AMB-32 Nursing Protocol for: Tecartus CAR-T - mantle cell lymphoma (mcl) for Haematology & TYA Ambulatory Care Unit

NHS England CAR-T service specifications for Kymriah for DLBCL and ALL

NHS England CAR-T service specifications for Yescarta for DLBCL

NHS England CAR-T service specifications for Tecartus for MCL

APH-165 Allogeneic Transplant - Follow up and Late Effects

CAR-T DLBCL post transplant follow up worksheet

APH-68 CAR-T ALL post transplant follow up worksheet

Service specification for the delivery of Chimeric Antigen Receptor T Cell (CAR-T) Therapy (all indications, all ages)

Kymriah SPC <https://www.medicines.org.uk/emc/product/9456>

Yescarta SPC <https://www.medicines.org.uk/emc/product/9439>

Tecartus SPC <https://www.medicines.org.uk/emc/product/11987/smpc#gref>

**PRINTED COPIES MAY NOT BE THE MOST CURRENT VERSION OF THIS DOCUMENT. ALWAYS REFER TO Q PULSE FOR THE MOST UP TO DATE VERSION**

Chimeric Antigen Receptor T-Cell Therapy Discharge and Follow-Up. CAR-T Service Pathway – Post Infusion

Version 4.0

Index Number: CLN-99

Author:

Effective Date: April 2025

Review Date: See Q Pulse

Page 10 of 11



Breyanzi SPC

[https://www.medicines.org.uk/emc/product/100499/smpchttp://igd.mdsas.com/wp-content/uploads/NHSE Commissioning Criteria for the use of lg V1.4 November 2019.pdf](https://www.medicines.org.uk/emc/product/100499/smpchttp://igd.mdsas.com/wp-content/uploads/NHSE_Commissioning_Criteria_for_the_use_of_lg_V1.4_November_2019.pdf)

Management of adults and children undergoing chimeric antigen receptor T-cell therapy 2022 Ann Oncol. 2022 Mar;33(3):259-275.  
<https://pubmed.ncbi.nlm.nih.gov/34923107/>

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events (2020) Vol 8(2) The Journal for ImmunoTherapy of Cancer <https://jitc.bmj.com/content/8/2/e001511>

## 10.0 Approval Process & Review Process

All new procedures are approved by the Clinical Program Director or approved designate before implementation of the procedure.

Revisions to existing procedures will be approved by the Clinical Director or approved designate prior to implementation.

Procedures will be reviewed every 2 years as a minimum

**PRINTED COPIES MAY NOT BE THE MOST CURRENT VERSION OF THIS DOCUMENT. ALWAYS REFER TO Q PULSE FOR THE MOST UP TO DATE VERSION**

Chimeric Antigen Receptor T-Cell Therapy Discharge and Follow-Up.  
CAR-T Service Pathway – Post Infusion

Version 4.0

Index Number: CLN-99

Author:

Effective Date: April 2025

Review Date: See Q Pulse

Page 11 of 11